EANS-News: DEWB investment holding: NOXXON´s SDF-1 inhibitor NOX-A12 completes Phase I

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Subtitle: Preclinical data in models of hematological tumors to be
presented at ASH conference

Berlin, Germany, 12 December 2011 (euro adhoc) - NOXXON Pharma, a
biopharmaceutical company pioneering the development of a new class
of proprietary therapeutics called Spiegelmers, today announced the
completion of Phase I single and multiple dose clinical trials of its
SDF-1 inhibitor NOX-A12. In Phase I studies with healthy volunteers
single doses of NOX-A12 up to 10.8 mg/kg and daily doses up to 2
mg/kg for five days were found to be safe and well tolerated and
resulted in dose-dependent mobilization of white blood cells and
CD34+ cells as predicted by preclinical studies.

NOX-A12 pre-clinical results in hematological malignancies will be
presented in a talk at the annual meeting of the American Society of
Hematology (ASH) in San Diego, USA from 10-13 December 2011. Members
of NOXXON´s drug development team and collaboration partners will be
at the ASH conference to explain the mode of action and clinical
potential of this innovative drug candidate.

The titles and contributors to the three NOX-A12 presentations at ASH
are as follows:

• Oral presentation Monday, December 12, 7:15 PM; Session 652; Room
6A L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (NOX-A12) Disrupts
the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu
In Vivo, Leading to Enhanced Sensitivity to Bortezomib A. M. Roccaro,
A. Sacco, P. Qaung, A. Azab, P. Maiso, F. Azab, Y. Zhang, G. C. Issa,
Y. Liu, H. T. Ngo, A. Kruschinski, I. M. Ghobrial

• Poster presentation Sunday, December 11, 6:00 PM-8:00 PM; Session
711; Poster II in Hall GH Rapid and Efficient Mobilization of Murine
Hematopoietic Stem and Progenitor Cells with NOX-A12, a New
Spiegelmers-Based CXCR4/SDF-1(CXCL12) Antagonist M. Scheller, F.
Schwoebel, D. Vossmeyer, A. Leutz

• Poster presentation Monday, December 12, 6:00 PM-8:00 PM; Session
641; Poster III in Hall GH The Spiegelmer NOX-A12, a novel SDF-1
(CXCL12) inhibitor, and its effects on Chronic Lymphocytic Leukemia
(CLL) cell migration. J. Hoellenriegel, D. Zboralski, Z. Estrov, W.
G. Wierda, M. Keating, A. Kruschinski, J. A. Burger

Based on compelling pre-clinical data in hematological and solid
tumors, NOXXON believes that NOX-A12 has the potential to be
developed for treatment of multiple oncology indications. Initiation
of the first Phase IIa trial of NOX-A12 in a hematological tumor
indication is planned early in 2012, subject to regulatory and ethics
committee approvals.

- ends -

About NOXXON Pharma AG NOXXON Pharma is a biopharmaceutical company
pioneering the development of a new class of proprietary therapeutics
called Spiegelmers. Spiegelmers are the chemically synthesized,
non-immunogenic alternative to antibodies. NOXXON has a diversified
portfolio of clinical stage Spiegelmer® therapeutics:

• NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) and is
currently in Phase Ib for complications of type 2 diabetes including
nephropathy. A Phase IIa study in diabetics with renal impairment is
currently in preparation. • NOX-A12 targets SDF-1 (CXCL12), a
chemokine mediator of metastasis and resistance to chemotherapy in
cancer, and has completed Phase I. Clinical Trial Applications have
been submitted for Phase IIa studies in hematological oncology
indications. • NOX-H94 targets hepcidin, the key regulator of iron
metabolism and mediator of iron restriction in anemia of chronic
disease, and is currently in a comprehensive single and multiple
ascending dose Phase I study.

The Spiegelmer® platform provides the company with powerful and
unique discovery capabilities, which have generated a number of
additional leads under preclinical investigation. Located in Berlin,
Germany, NOXXON is a well-financed mature biotech company with a
strong syndicate of international investors, approx. 60 employees and
a highly experienced management team.

For more information, please visit: www.noxxon.com

Contact:

NOXXON Pharma AG College Hill Life Sciences
Emmanuelle Delabre Dr. Robert Mayer
T: +49-(0)30-726247-100 T: +49-(0)89-57001806
edelabre@noxxon.com robert.mayer@collegehill.com

Notes for editors:

About NOX-A12

NOX-A12 specifically antagonizes stromal cell-derived factor-1
(SDF-1), a chemokine which attracts and activates immune- and
non-immune cells. SDF-1 binds with high affinity to the chemokine
receptors CXCR4 and CXCR7. The SDF-1 / CXCR4 / CXCR7 axis has been
shown to play a role in stem cell mobilization, vasculogenesis, tumor
growth and metastasis. Inhibition of the SDF-1 binding to its
receptors sensitizes tumor cells to chemotherapy and in some solid
tumors prevents invasion and metastasis, suggesting that NOX-A12 in
combination with chemotherapy could be beneficial in the treatment of
various cancers.

NOX-A12 has shown promising activity in models of stem cell
mobilization and both hematological and solid tumors. In Phase I
studies with healthy volunteers, single doses of NOXXON´s SDF-1
inhibitor, NOX-A12, up to 10.8 mg/kg and daily doses up to 2 mg/kg
for five days were found to be safe and well tolerated and resulted
in dose-dependent mobilization of white blood cells and CD34+ cells
as predicted by preclinical studies.

NOXXON received grant support within the program "KMU-innovativ" from
the German Federal Ministry of Education and Research (BMBF) for the
preclinical program and the Phase I clinical trials with NOX-A12.

Further information about the planned clinical trial in relapsed CLL
patients is available at ClinicalTrials.gov (ID: NCT01486797).

Further inquiry note:
Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Leutragraben 1
D-07743 Jena
phone: +49 (0)3641 573 3600
FAX: +49 (0)3641 573 3610
mail: ir@dewb-vc.com
WWW: http://www.dewb-vc.com
sector: Financial & Business Services
ISIN: DE0008041005
indexes:
stockmarkets: free trade: Berlin, Stuttgart, München, Open Market / Entry
Standard: Frankfurt
language: English